Health Benefits Hub

December 2, 2021

Drug Plans Decoded: Biosimilars Part 4.

Biosimilars in Canada: what plan sponsors can do. For plan sponsors that want to take advantage of the savings available through biosimilar biologics, several options are available. Since the regulatory environment prohibits automatic interchange with the reference biologic, plan design is very much a driver of success for the selected […]

Sign up for email updates.

All the latest articles delivered directly to your inbox.

Sign up

We will use your email address to send you our newsletter.
All communications will be from TELUS Health.

All fields are required

First name

Last name

Language

Company Name

Job title

Select the option that best describes your role

We will use your email address to send you our newsletter. All communications will be coming from TELUS Health. Our contact information is: 630 René-Lévesque Blvd. West, 22nd floor, Montreal, QC J4K 5B1. Email: telushealth@telus.com. Phone: 1-877-999-4669. We assure you that your email address will not be shared with any third party. You can withdraw your consent to receive electronic messages from TELUS Health at any time.

November 29, 2021

Keep up with current industry trends.

Drug Plans Decoded: Biosimilars Part 4.

Diabetes and Canadian Employers.

Drug Plans Decoded: Biosimilars Part 3

Can technology create great plan member experiences?